Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

Cardio-Oncology
Sarju GanatraSteven E Lipshultz

Abstract

Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of anthracyclines, but in the USA and some European countries, its use had been restricted to adults with advanced breast cancer receiving a cumulative doxorubicin (an anthracycline) dose > 300 mg/m2. We evaluated the off-label use of dexrazoxane as a cardioprotectant in adult patients with preexisting cardiomyopathy, undergoing anthracycline chemotherapy. Between July 2015 and June 2017, five consecutive patients, with preexisting, asymptomatic, systolic left ventricular (LV) dysfunction who required anthracycline-based chemotherapy, were concomitantly treated with off-label dexrazoxane, administered 30 min before each anthracycline dose, regardless of cancer type or stage. Demographic, cardiovascular, and cancer-related outcomes were compared to those of three consecutive patients with asymptomatic cardiomyopathy treated earlier at the same hospital without dexrazoxane. Mean age of the five dexrazoxane-treated patients and three patients treated without dexrazoxane was 70.6 and 72.6 years, respectively. All five dexrazoxane-tr...Continue Reading

References

Oct 1, 1971·Cancer·E MiddlemanE Frei
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M SwainR A Gams
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M SwainR A Gams
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LopezC L Maini
Nov 3, 1998·Lancet·L SamuelP Shaw
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M RybergP Dombernowsky
Dec 4, 2003·Free Radical Biology & Medicine·Brian B HasinoffXing Wu
Jul 13, 2004·The New England Journal of Medicine·Steven E LipshultzStephen E Sallan
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron K TebbiCindy L Schwartz
Mar 19, 2008·Heart·Steven E LipshultzRebecca E Scully
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J Barrett-LeeM W Verrill
Jul 28, 2010·Archives of Internal Medicine·Helena J van der PalLeontien C Kremer
Jun 1, 2012·American Journal of Hematology·Anat RabinovichItai Levi
Jul 5, 2012·Current Cardiology Reviews·Maria Volkova, Raymond Russell
Mar 22, 2013·The New England Journal of Medicine·Douglas B Sawyer
Jan 5, 2014·Journal of Clinical Pharmacy and Therapeutics·S LimatE Deconinck
Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Aug 31, 2014·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Juan Carlos PlanaPatrizio Lancellotti
May 8, 2015·Circulation·John D Groarke, Anju Nohria
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J ChowSaro H Armenian
Jun 28, 2016·The Canadian Journal of Cardiology·Husam Abdel-QadirPaaladinesh Thavendiranathan
Dec 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saro H ArmenianDaniel Lenihan
Mar 24, 2018·Journal of the American College of Cardiology·Syed S MahmoodTomas G Neilan
May 17, 2018·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hyery KimHee Young Shin
May 29, 2018·The Oncologist·Sarju Ganatra, Tomas G Neilan
Jun 23, 2018·Journal of the American College of Cardiology·Sarju Ganatra, Salim S Hayek
Dec 24, 2018·JACC. Clinical Electrophysiology·Sarju GanatraAnju Nohria

❮ Previous
Next ❯

Citations

Jun 10, 2020·Current Oncology Reports·Valentina BracunRudolf A de Boer
Sep 10, 2020·Frontiers in Pharmacology·Nonhlakanipho F SangweniRabia Johnson
Apr 1, 2020·Frontiers in Cardiovascular Medicine·Alessandra MurabitoAlessandra Ghigo
Jan 31, 2020·Frontiers in Cardiovascular Medicine·Sherry-Ann Brown
Mar 11, 2020·Cardio-Oncology·Neha BansalSteven E Lipshultz
Jan 22, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CuriglianoUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Apr 10, 2021·Molecular and Cellular Biochemistry·Sonu S VargheseDavinder S Jassal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.